WO2006114384A1 - Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester - Google Patents

Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester Download PDF

Info

Publication number
WO2006114384A1
WO2006114384A1 PCT/EP2006/061694 EP2006061694W WO2006114384A1 WO 2006114384 A1 WO2006114384 A1 WO 2006114384A1 EP 2006061694 W EP2006061694 W EP 2006061694W WO 2006114384 A1 WO2006114384 A1 WO 2006114384A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
benzisoxazol
pyrimidin
fluoro
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/061694
Other languages
French (fr)
Inventor
Thomas Frederik Ernestine Spittaels
Joannes Petrus Van Dun
Jurgen Aloïs VERBRAEKEN
Benny Wouters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN2006800138227A priority Critical patent/CN101163702B/en
Priority to JP2008508198A priority patent/JP5249748B2/en
Priority to EP06754754A priority patent/EP1879890A1/en
Priority to US11/912,452 priority patent/US20080214808A1/en
Priority to HK08108269.9A priority patent/HK1117521B/en
Publication of WO2006114384A1 publication Critical patent/WO2006114384A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention concerns a process for preparing aseptic crystalline 3-[2-[4-(6- fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2- methyl-4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) substantially free of 3-[2- [4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy- 2-methyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l ,2-benzisoxazol- 3-yl)-l-piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l,2-a]
  • EP-0,368,388 (US-5,158,952), 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l ,2-a]pyrimidin- 4-one palmitate ester of formula (I) is disclosed.
  • EP-0,904,081 and EP-1,033,987 disclose aqueous suspensions of submicron' paliperidone palmitate (I) suitable as depot formulations which are therapeutically effective for about a month when administered intramuscularly to a warm-blooded subject.
  • aseptic formulations of paliperidone palmitate (I) were initially obtained by gamma irradiation.
  • step b) The terms 'aseptic' and 'sterile' are used herein interchangeably and mean 'free or freed from micro-organisms'. All process steps following step b) are conducted aseptically under fully closed conditions applying isolator technology.
  • the process comprising the steps a), b), c), e), f) and g), that is the process comprising two heating cycles, is the more robust one as it allows the best control over the crystallization process and the particle size distribution of the particles.
  • step e) and the rate of cooling applied in step f) are particular important to the particle size distribution of aseptic paliperidone palmitate ester (I). Reheating to just below reflux temperature ( ⁇ 77 0 C) and cooling at a rate of
  • Reheating to reflux temperature (78 0 C) and rapid cooling yields crystals having an average particle size of about 20 to 30 micron. It is preferable that the rate of cooling in step f) is as rapid as possible. Notwithstanding the aforementioned, a process comprising the steps a), b), c) and d), that is a process comprising only one heating cycle, is also feasible as can be seen from particular experiments in the experimental part.
  • a process as described hereinbefore comprising the further steps of h) suspending the crystals obtained in steps d) or g) in a sterilized solution of water comprising a surfactant, and optionally a suspending agent and a buffer; i) grinding the suspension of step h) in the presence of a grinding medium to particles having a specific surface area > 4 m 2 /g; j) sieving the suspension of step i) to remove the grinding medium; k) diluting and mixing the solution of step j) with a sterilized solution of water optionally comprising a suspending agent, a buffer and an antioxidant; and
  • the sterilized solution of water comprising a surfactant, and optionally a suspending agent and a buffer is prepared by dissolving a surfactant, and optionally a suspending agent and a buffer in water for injection and sterilizing the thus obtained solution by heating for 30 minutes at 121 0 C, or by microfiltration.
  • the grinding process is a wet milling process as disclosed in EP -0,499,299.
  • the particles of the present invention have a surfactant or surface modifier adsorbed on the surface thereof in an amount sufficient to maintain a specific surface area > 4 m 2 /g (i.e. corresponding to an average particle size of less than 2,000 ran), preferably the specific surface area > 6 m 2 /g, and in particular is in the range from 10 to 16 m 2 /g.
  • Useful surface modifiers are believed to include those which physically adhere to the surface of the active agent but do not chemically bond thereto.
  • Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants. Preferred surface modifiers include nonionic and anionic surfactants.
  • excipients include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene allcyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available TweensTM, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethyleellulose calcium, carboxymethyleellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium
  • Particularly preferred surface modifiers include polyvinylpyrrolidone; tyloxapol; poloxamers, such as PluronicTM ⁇ 68, Fl 08 and F 127 which are block copolymers of ethylene oxide and propylene oxide available from BASF; poloxamines, such as TetronicTM 908 (T908) which is a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethyl enediamine available from BASF; dextran; lecithin; Aerosol OTTM (AOT) which is a dioctyl ester of sodium sulfosuccinic acid available from Cytec Industries; DuponolTM P which is a sodium lauryl sulfate available from DuPont; TritonTM X-200 which is an alkyl aryl polyether sulfonate available from Rohm and Haas; TweensTM 20, 40, 60 and 80 which are polyoxyethylene sorbitan
  • CarbowaxTM 3550 and 934 which are polyethylene glycols available from Union Carbide; CrodestaTM Fl 10 which is a mixture of sucrose stearate and sucrose distearate available from Croda Inc.; CrodestaTM SL-40 which is available from Croda, Inc.; hexyldecyl trimethyl ammonium chloride (CTAC); bovine serum albumin and SA90HCO which is Ci 8 H 17 CH 2 (CON(CH 3 )CH 2 (CHOH) 4 CH 2 OH) 2 .
  • CAC hexyldecyl trimethyl ammonium chloride
  • SA90HCO which is Ci 8 H 17 CH 2 (CON(CH 3 )CH 2 (CHOH) 4 CH 2 OH) 2 .
  • the surface modifiers which have been found to be particularly useful include tyloxapol and a poloxamer, preferably, PluronicTM F108 and PluronicTM F68, and polyoxyethylene sorbitan fatty acid esters, preferably TweenTM 20.
  • PluronicTM Fl 08 corresponds to poloxamer 338 and is the polyoxyethylene, polyoxypropylene block copolymer that conforms generally to the formula HO[CH 2 CH 2 O] X [CH(CH 3 )CH 2 O] X [CH 2 CH 2 O) 2 H in which the average values of x, y and z are respectively 128, 54 and 128.
  • Other commercial names of poloxamer 338 are Hodag NonionicTM 1 108-F available from Hodag, and SynperonicTM PE/F108 available from ICI Americas.
  • the optimal relative amount of paliperidone palmitate and the surface modifier depends on various parameters.
  • the optimal amount of the surface modifier can depend, for example, upon the particular surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the surface area of (I), etc.
  • the specific surface modifier preferably is present in an amount of 0.1 to 1 mg per square meter surface area of (I).
  • PluronicTM Fl 08 is used as a surface modifier, a ratio (w/w) of (I) : surface modifier of approximately 6 : 1 is preferred.
  • TweenTM 20 is the surface modifier, a ratio (w/w) of (I) : surface modifier of approximately 13 : 1 is preferred.
  • an effective average particle size of less than 2,000 nm means that at least 90 % of the particles have a diameter of less than 2,000 nm when measured by art- known conventional techniques, such as sedimentation field flow fractionation, photon correlation spectroscopy or disk centrifugation.
  • the effective average particle size it is preferred that at least 95 % and, more preferably, at least 99 % of the particles have a particle size of less than the effective average particle size, e.g. 2,000 nm. Most preferably, essentially all of the particles have a size of less than 2,000 nm.
  • the grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in form having an average size less than 3 mm and, more preferably, less than 1 mm. Such media desirably can provide the particles of the invention with shorter processing times and impart less wear to the milling equipment.
  • the selection of the material for the grinding media is believed not to be critical. However, 95 % ZrO stabilized with magnesia, zirconium silicate, and glass grinding media provide particles having levels of contamination which are believed to be acceptable for the preparation of pharmaceutical compositions. Further, other media, such as polymeric beads, stainless steel, titania, alumina and 95 % ZrO stabilized with yttrium, are useful.
  • Preferred grinding media have a density greater than 2.5 g/cm3 and include 95 % ZrO stabilized with magnesia and polymeric beads.
  • the attrition time can vary widely and depends primarily upon the particular mechanical means and processing conditions selected.
  • the particles must be reduced in size at a temperature which does not significantly degrade the antipsychotic agent. Processing temperatures of less than 30 to 40 0 C are ordinarily preferred. If desired, the processing equipment may be cooled with conventional cooling equipment. The method is conveniently carried out under conditions of ambient temperature and at processing pressures which are safe and effective for the milling process.
  • Aqueous compositions according to the present invention conveniently further comprise a suspending agent, a buffer and an antioxidant.
  • Particular ingredients may function as two or more of these agents simultaneously, e.g. behave like a preservative and a buffer, or behave like a buffer and an isotonizing agent, or like a buffering agent and antioxidant.
  • Suitable suspending agents for use in the aqueous suspensions according to the present invention are cellulose derivatives, e.g. methyl cellulose, sodium carboxymethyl cellulose and hydroxypropyl methyl cellulose, polyvinylpyrrolidone, alginates, chitosan, dextrans, gelatin, polyethylene glycols, polyoxyethylene- and polyoxy- propylene ethers.
  • cellulose derivatives e.g. methyl cellulose, sodium carboxymethyl cellulose and hydroxypropyl methyl cellulose
  • polyvinylpyrrolidone alginates
  • chitosan alginates
  • dextrans dextrans
  • gelatin polyethylene glycols
  • polyoxyethylene- and polyoxy- propylene ethers Preferably sodium carboxymethyl cellulose is used in a concentration of 0.5 to 2 %, most preferably 1 % (w/v).
  • Suitable wetting agents for use in the aqueous suspensions according to the present invention are polyoxyethylene derivatives of
  • polysorbate 20 and polysorbate 80 lecithin, polyoxyethylene- and polyoxypropylene ethers, sodium deoxycholate.
  • polysorbate 20 is used in a concentration of 0.5 to 3 %, more preferably 0.5 to 2 %, most preferably 1.1 % (w/v).
  • Suitable buffering agents are salts of weak acids and should be used in amount sufficient to render the dispersion neutral to very slightly basic (up to pH 8.5), preferably in the pH range of 7 to 7.5. Particularly preferred is the use of a mixture of disodium hydrogen phosphate (anhydrous) (typically about 0.9 % (w/v)) and sodium dihydrogen phosphate monohydrate (typically about 0.6 % (w/v)). This buffer also renders the dispersion isotonic and, in addition, less prone to flocculation of the ester suspended therein. Citric acid is useful as an antioxidant.
  • Suitable sterile containers in which the suspension of paliperidone palmitate ester (I) may be filled comprise sterile holding vessels as well sterile syringes which then may packaged with appropriate needles into end-user packages.
  • the present invention also concerns aseptic crystalline 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) substantially free of 3-[2-[4-(6-fluoro- 1 ,2-benzisoxazol-3-yl)- 1 -piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l ,2-a]pyrimi
  • the invention relates to aseptic crystalline 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l ,2-a]pyrimidin-4-one palmitate ester (I) containing less than 0.5 % of S-fZ- ⁇ -C ⁇ -fluoro-l ⁇ -benzisoxazol-S-yO-l-piperidiny ⁇ ethylJ- ⁇ j T ⁇ -tetrahydro- ⁇ hydroxy-2-methyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one (II- a), 3 -[2-[4-(6-fluoro- 1 ,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H
  • the invention concerns aseptic crystalline 3-[2-[4-(6-fluoro-l,2-benzisoxazol- 3-yl)-l -piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[ 1 ,2-a]- pyrimidin-4-one palmitate ester (I) substantially free of 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l ,2-a]pyrimi
  • Compound (I) was irradiated with various doses of gamma rays in different containers.
  • the amount of the breakdown products (II) i.e. the sum of the amounts of compound (II-a) and (II-b)] and (III) increased dose-dependently.
  • Example 1 GMP batches in pilot installation
  • VHP vaporized hydrogen peroxide
  • a reaction vessel was charged with 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidmyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]pvrimidin- 4-one palmitate ester (2.5 kg) and ethanol parenteral grade (7 L/kg) and heated to reflux temperature (78 - 79 0 C) while stirring. The product dissolved at about 70 0 C. The solution was filtered at 76 0 C over a sterile 0.22 ⁇ m filter into a glass crystallization reactor. The sterile filter was then washed with heated ethanol (1 L/kg).
  • the crystals were then filtered off, washed with ethanol parenteral grade (1 L/kg) and dried in vacuo at 50 0 C in Tyvek bags so as to prevent dust formation.
  • Example 2 Scale up and equipment set upin Hastelloy C22 mini plant vessels of 30L, 60L and 160L.
  • a reactor was charged with 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- pi ⁇ eridinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]- pyrimidin-4-one palmitate ester and ethanol parenteral grade (8 L/kg) and heated to reflux temperature (78 - 79 0 C) while stirring. The product dissolved at about 70 0 C.
  • the reaction mixture is then cooled to room temperature whereupon the product crystallized.
  • the thus obtained suspension was reheated again.
  • the solution was cooled using differing cooling gradients (in consecutive experiments, the mixture was reheated and cooled again; after each cooling gradient, a sample was taken and isolated using a filter. The particle characteristics were determined.
  • Example 3 Crystallization in stainless steel reactor of 50L All equipment was sterilized using dry heat sterilization.
  • the filtrate was reheated to reflux and then cooled to room temperature whereupon the product crystallized.
  • the thus obtained suspension was reheated again.
  • the solution was cooled using differing cooling gradients (in consecutive experiments, the mixture was reheated and cooled again; after each cooling gradient, a sample was taken and isolated using a filter.
  • the crystals were dried in vacuo at 50 0 C in Tyvek bags so as to prevent dust formation and the particle characteristics were determined.
  • Zirconium beads wear cleaned and rinsed using water for injections and then depyrogenised by dry heat (120 min at 26O 0 C). Water for injections was transferred into a SS container. Polysorbate 20 was added and dissolved by mixing. The solution was sterilized by filtration through a sterile 0.2 ⁇ m filter into a sterilized SS container. Paliperidone palmitate ester (sterile grade) as prepared in the previous examples was dispersed into the solution and mixed until homogeneous. The suspension was milled aseptically in the grinding chamber using Zirconium beads as grinding media until the required particle size was reached. The suspension was filtered aseptically through a 40 ⁇ m filter into a sterilized SS container
  • Water for injections was transferred into a SS container, citric acid monohydrate parenteral, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium hydroxide all use, polyethylene glycol 4000 were added and mixed until dissolved. This solution was sterilized by filtration through a sterile 0.2 ⁇ m filter and transferred aseptically into the suspension. The final suspension was mixed until homogeneous. The suspension was filled aseptically into sterile syringes. The target dose volume was between 0.25 ml and 1.50 ml depending on the dose needed.
  • the empty syringes with pre-assembled tip-caps were sterilized by gamma-irradiation (dose > 25 kGy).
  • the rubber plunger stoppers were sterilized by means of steam sterilization (F 0 > 15).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention concerns a process for preparing aseptic crystalline 3-[2-[4- (6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy- 2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) substantially free of 3-[2-[4-(6-fluoro- 1 ,2-benzisoxazol-3-yl)- 1 -piperidinyl]ethyl]-6,7,8,9-tetrahydro-9- hydroxy-2-methyl-4H-pyrido[ 1 ,2-a] pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l ,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l ,2-a]- pyrimidin-4-one (II-b), and 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]- ethyl]-6,7,8,9-tetrahydro-2-methyl-9-pentadecyl-4H-pyrido[l ,2-a]pyrimidin-4-one (III), and having an average particle size ranging from 20 to 150 μm.

Description

PREPARATION OF ASEPTIC 3-[244-(6-FLUORQ-I ^-BENZISQXAZOL-S- YL)-l-PIPERIDINYLlETHYL1-6,7.8.9-TETRAHYDRO-9-HYDROXY-2- METHYL-4H-PYRIDOrL2-alPYRIMIDIN-4-ONE PALMITATE ESTER
Background of the invention
The present invention concerns a process for preparing aseptic crystalline 3-[2-[4-(6- fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2- methyl-4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) substantially free of 3-[2- [4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy- 2-methyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l ,2-benzisoxazol- 3-yl)-l-piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one (II-b), and 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9- tetrahydro-2-methyl-9-pentadecyl-4H-pyrido[l,2-a]pyrimidin-4-one (III), and having an average particle size ranging from 20 to 150 μm, preferably from 20 to 80 μm. 3-[2-[4-(6-Fluoro-l ,2-benzisoxazol-3-yl)-l -piperidinyl]ethyl]-6,7,8,9-tetrahydro-9- hydroxy-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) is also known as paliperidone palmitate ester; and the compound of formula (II-a) is also known as paliperidone.
In EP-0,368,388 (US-5,158,952), 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l ,2-a]pyrimidin- 4-one palmitate ester of formula (I) is disclosed.
Figure imgf000002_0001
EP-0,904,081 and EP-1,033,987 disclose aqueous suspensions of submicron' paliperidone palmitate (I) suitable as depot formulations which are therapeutically effective for about a month when administered intramuscularly to a warm-blooded subject. During pharmaceutical development, aseptic formulations of paliperidone palmitate (I) were initially obtained by gamma irradiation. Upon analysis of irradiated paliperidone (I), the process was found to give three breakdown products : up to 0.24 % of 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)- 1 -piperidmyl]ethyl]-6,7,8,9-tetrahydro-9- hydroxy-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one (II-a) and 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)- 1 -piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[ 1 ,2-a]- pyrimidin-4-one (II-b) which in the analytical ΗPLC method co-eluted and are collectively designated (II) hereinafter,
Figure imgf000003_0001
and up to 0.46 % of 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]- 6,7,8,9-tetrahydro-2-methyl-9-pentadecyl-4H-pyrido[l,2-a]pyrimidin-4-one (III).
Figure imgf000003_0002
In order to avoid the formation of the breakdown products (II) [i.e. (II-a) and (II-b)] and (III), various other techniques to sterilize compound (I) were considered. Sterilization by microfiltration is impossible because the aqueous suspension of 'submicron' paliperidone palmitate (I) will block the filter pores. Heat sterilization proves impossible as compound (I) melts between 116.5 and 119.5 0C.
The double objective of developing an aseptic production process for paliperidone palmitate (I) while managing its particle size distribution is achieved in the present invention which provides a process for preparing aseptic crystalline 3-[2-[4-(6-fluoro- l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l ,2-a]pyrimidin-4-one palmitate ester of formula (I)
Figure imgf000004_0001
substantially free of 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7-dihydro-2- methyl-4H-pyrido[l,2-a]pyrimidin-4-one (n_b) and 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-9-pentadecyl-
4H-pyrido[ 1 ,2-a]pyrimidin-4-one (III), and having an average particle size ranging from 20 to 150 μm, preferably from 20 to 80 μm, comprising the steps of a) heating 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one palmitate ester (I) and ethanol parenteral grade to 72 0C to 78 0C; b) filtering the solution of step a) over a sterile 0.22 μm filter into a sterile crystallization reactor; c) allowing 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l ,2-a]pyrimidin-4-one palmitate ester (I) to crystallize while cooling; and either d) filtering off the thus obtained crystals; or e) reheating the thus obtained suspension again to 72 0C to 78 0C; f) allowing 3-[2-[4-(6-fluoro- 1 ,2-benzisoxazol-3-yl)- 1 -piperidinyl] ethyl] - 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l ,2-a]pyrimidin-4-one palmitate ester (I) to crystallize while cooling; and g) filtering off the thus obtained crystals.
The terms 'aseptic' and 'sterile' are used herein interchangeably and mean 'free or freed from micro-organisms'. All process steps following step b) are conducted aseptically under fully closed conditions applying isolator technology.
The process comprising the steps a), b), c), e), f) and g), that is the process comprising two heating cycles, is the more robust one as it allows the best control over the crystallization process and the particle size distribution of the particles.
The temperature achieved in step e) and the rate of cooling applied in step f) are particular important to the particle size distribution of aseptic paliperidone palmitate ester (I). Reheating to just below reflux temperature (< 77 0C) and cooling at a rate of
0.5 °C/min yields crystals having an average particle size of about 80 micron.
Reheating to just below reflux temperature (< 77 0C) and cooling at a rate of 1 °C/min yields crystals having an average particle size of about 50 to 60 micron. In both instances, crystallization starts at about 60 0C. These conditions and parameters are equipment specific (here for a 30L reactor) and may vary when larger equipment is used.
Reheating to reflux temperature (78 0C) and rapid cooling yields crystals having an average particle size of about 20 to 30 micron. It is preferable that the rate of cooling in step f) is as rapid as possible. Notwithstanding the aforementioned, a process comprising the steps a), b), c) and d), that is a process comprising only one heating cycle, is also feasible as can be seen from particular experiments in the experimental part.
In a further aspect of the invention, there is provided a process as described hereinbefore, comprising the further steps of h) suspending the crystals obtained in steps d) or g) in a sterilized solution of water comprising a surfactant, and optionally a suspending agent and a buffer; i) grinding the suspension of step h) in the presence of a grinding medium to particles having a specific surface area > 4 m2/g; j) sieving the suspension of step i) to remove the grinding medium; k) diluting and mixing the solution of step j) with a sterilized solution of water optionally comprising a suspending agent, a buffer and an antioxidant; and
1) filling the sieved suspension into a sterile container.
These further process steps are known from EP-0,904,081 and EP-1,033,987.
In particular, the sterilized solution of water comprising a surfactant, and optionally a suspending agent and a buffer is prepared by dissolving a surfactant, and optionally a suspending agent and a buffer in water for injection and sterilizing the thus obtained solution by heating for 30 minutes at 121 0C, or by microfiltration. The grinding process is a wet milling process as disclosed in EP -0,499,299.
The particles of the present invention have a surfactant or surface modifier adsorbed on the surface thereof in an amount sufficient to maintain a specific surface area > 4 m2/g (i.e. corresponding to an average particle size of less than 2,000 ran), preferably the specific surface area > 6 m2/g, and in particular is in the range from 10 to 16 m2/g. Useful surface modifiers are believed to include those which physically adhere to the surface of the active agent but do not chemically bond thereto.
Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants. Preferred surface modifiers include nonionic and anionic surfactants. Representative examples of excipients include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene allcyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens™, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethyleellulose calcium, carboxymethyleellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminate silicate, triethanolamine, polyvinyl alcohol (PVA), poloxamers, tyloxapol and polyvinylpyrrolidone (PVP). Most of these excipients are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, the Pharmaceutical Press, 1986. The surface modifiers are commercially available and/or can be prepared by techniques known in the art. Two or more surface modifiers can be used in combination.
Particularly preferred surface modifiers include polyvinylpyrrolidone; tyloxapol; poloxamers, such as Pluronic™ ¥68, Fl 08 and F 127 which are block copolymers of ethylene oxide and propylene oxide available from BASF; poloxamines, such as Tetronic™ 908 (T908) which is a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethyl enediamine available from BASF; dextran; lecithin; Aerosol OT™ (AOT) which is a dioctyl ester of sodium sulfosuccinic acid available from Cytec Industries; Duponol™ P which is a sodium lauryl sulfate available from DuPont; Triton™ X-200 which is an alkyl aryl polyether sulfonate available from Rohm and Haas; Tweens™ 20, 40, 60 and 80 which are polyoxyethylene sorbitan fatty acid esters available from ICI Speciality Chemicals; Span™ 20, 40, 60 and 80 which are sorbitan esters of fatty acids; Arlacel™ 20, 40, 60 and 80 which are sorbitan esters of fatty acids available from Hercules, Inc.;
Carbowax™ 3550 and 934 which are polyethylene glycols available from Union Carbide; Crodesta™ Fl 10 which is a mixture of sucrose stearate and sucrose distearate available from Croda Inc.; Crodesta™ SL-40 which is available from Croda, Inc.; hexyldecyl trimethyl ammonium chloride (CTAC); bovine serum albumin and SA90HCO which is Ci8H17CH2 (CON(CH3)CH2(CHOH)4CH2OH)2. The surface modifiers which have been found to be particularly useful include tyloxapol and a poloxamer, preferably, Pluronic™ F108 and Pluronic™ F68, and polyoxyethylene sorbitan fatty acid esters, preferably Tween™ 20.
Pluronic™ Fl 08 corresponds to poloxamer 338 and is the polyoxyethylene, polyoxypropylene block copolymer that conforms generally to the formula HO[CH2CH2O]X[CH(CH3)CH2O]X[CH2CH2O)2H in which the average values of x, y and z are respectively 128, 54 and 128. Other commercial names of poloxamer 338 are Hodag Nonionic™ 1 108-F available from Hodag, and Synperonic™ PE/F108 available from ICI Americas.
The optimal relative amount of paliperidone palmitate and the surface modifier depends on various parameters. The optimal amount of the surface modifier can depend, for example, upon the particular surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the surface area of (I), etc. The specific surface modifier preferably is present in an amount of 0.1 to 1 mg per square meter surface area of (I). In case Pluronic™ Fl 08 is used as a surface modifier, a ratio (w/w) of (I) : surface modifier of approximately 6 : 1 is preferred. When Tween™ 20 is the surface modifier, a ratio (w/w) of (I) : surface modifier of approximately 13 : 1 is preferred.
As used herein, an effective average particle size of less than 2,000 nm means that at least 90 % of the particles have a diameter of less than 2,000 nm when measured by art- known conventional techniques, such as sedimentation field flow fractionation, photon correlation spectroscopy or disk centrifugation. With reference to the effective average particle size, it is preferred that at least 95 % and, more preferably, at least 99 % of the particles have a particle size of less than the effective average particle size, e.g. 2,000 nm. Most preferably, essentially all of the particles have a size of less than 2,000 nm. The grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in form having an average size less than 3 mm and, more preferably, less than 1 mm. Such media desirably can provide the particles of the invention with shorter processing times and impart less wear to the milling equipment. The selection of the material for the grinding media is believed not to be critical. However, 95 % ZrO stabilized with magnesia, zirconium silicate, and glass grinding media provide particles having levels of contamination which are believed to be acceptable for the preparation of pharmaceutical compositions. Further, other media, such as polymeric beads, stainless steel, titania, alumina and 95 % ZrO stabilized with yttrium, are useful. Preferred grinding media have a density greater than 2.5 g/cm3 and include 95 % ZrO stabilized with magnesia and polymeric beads.
The attrition time can vary widely and depends primarily upon the particular mechanical means and processing conditions selected.
The particles must be reduced in size at a temperature which does not significantly degrade the antipsychotic agent. Processing temperatures of less than 30 to 40 0C are ordinarily preferred. If desired, the processing equipment may be cooled with conventional cooling equipment. The method is conveniently carried out under conditions of ambient temperature and at processing pressures which are safe and effective for the milling process.
Aqueous compositions according to the present invention conveniently further comprise a suspending agent, a buffer and an antioxidant. Particular ingredients may function as two or more of these agents simultaneously, e.g. behave like a preservative and a buffer, or behave like a buffer and an isotonizing agent, or like a buffering agent and antioxidant.
Suitable suspending agents for use in the aqueous suspensions according to the present invention are cellulose derivatives, e.g. methyl cellulose, sodium carboxymethyl cellulose and hydroxypropyl methyl cellulose, polyvinylpyrrolidone, alginates, chitosan, dextrans, gelatin, polyethylene glycols, polyoxyethylene- and polyoxy- propylene ethers. Preferably sodium carboxymethyl cellulose is used in a concentration of 0.5 to 2 %, most preferably 1 % (w/v). Suitable wetting agents for use in the aqueous suspensions according to the present invention are polyoxyethylene derivatives of sorbitan esters, e.g. polysorbate 20 and polysorbate 80, lecithin, polyoxyethylene- and polyoxypropylene ethers, sodium deoxycholate. Preferably polysorbate 20 is used in a concentration of 0.5 to 3 %, more preferably 0.5 to 2 %, most preferably 1.1 % (w/v).
Suitable buffering agents are salts of weak acids and should be used in amount sufficient to render the dispersion neutral to very slightly basic (up to pH 8.5), preferably in the pH range of 7 to 7.5. Particularly preferred is the use of a mixture of disodium hydrogen phosphate (anhydrous) (typically about 0.9 % (w/v)) and sodium dihydrogen phosphate monohydrate (typically about 0.6 % (w/v)). This buffer also renders the dispersion isotonic and, in addition, less prone to flocculation of the ester suspended therein. Citric acid is useful as an antioxidant.
Suitable sterile containers in which the suspension of paliperidone palmitate ester (I) may be filled comprise sterile holding vessels as well sterile syringes which then may packaged with appropriate needles into end-user packages.
The present invention also concerns aseptic crystalline 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) substantially free of 3-[2-[4-(6-fluoro- 1 ,2-benzisoxazol-3-yl)- 1 -piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l ,2-a]pyrimidin-4-one (II-b), and 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2- methyl-9-pentadecyl-4H-pyrido[l,2-a]pyrimidin-4-one (III), and having an average particle size ranging from 20 to 80 μm.
More in particular, the invention relates to aseptic crystalline 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l ,2-a]pyrimidin-4-one palmitate ester (I) containing less than 0.5 % of S-fZ-^-Cβ-fluoro-l^-benzisoxazol-S-yO-l-piperidiny^ethylJ-όjT^^-tetrahydro-^ hydroxy-2-methyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one (II- a), 3 -[2-[4-(6-fluoro- 1 ,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l,2-a]- pyrimidin-4-one (II-b), and less than 0.01 % of 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3- yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-9-pentadecyl-4H-pyrido[l,2-a]- pyrimidin-4-one (III), and having an average particle size ranging from 20 to 80 μm.
Further, the invention concerns aseptic crystalline 3-[2-[4-(6-fluoro-l,2-benzisoxazol- 3-yl)-l -piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[ 1 ,2-a]- pyrimidin-4-one palmitate ester (I) substantially free of 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l ,2-a]pyrimidin-4-one (II-b), and 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2- methyl-9-pentadecyl-4H-pyrido[l,2-a]pyrimidin-4-one (III), and having a specific surface area > 4 m /g.
Experimental Part Comparative Example
Compound (I) was irradiated with various doses of gamma rays in different containers. The amount of the breakdown products (II) [i.e. the sum of the amounts of compound (II-a) and (II-b)] and (III) increased dose-dependently.
Figure imgf000011_0001
Figure imgf000012_0001
Example 1 : GMP batches in pilot installation
All equipment was sterilized using the following techniques:
- steam sterilization
- dry heat sterilization
- vaporized hydrogen peroxide (VHP) sterilization
- gamma irradiation
To improve the sterility assurance of the process, all critical handlings with regard to sterility were performed in an isolator.
A reaction vessel was charged with 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidmyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]pvrimidin- 4-one palmitate ester (2.5 kg) and ethanol parenteral grade (7 L/kg) and heated to reflux temperature (78 - 79 0C) while stirring. The product dissolved at about 70 0C. The solution was filtered at 76 0C over a sterile 0.22 μm filter into a glass crystallization reactor. The sterile filter was then washed with heated ethanol (1 L/kg).
The filtrate cooled to room temperature whereupon the product crystallized. The thus obtained suspension was either filtered off or reheated again. Reheating to just below reflux temperature (< 77 0C) and cooling at a rate of 0.5 °C/min yielded crystals having an average particle size of about 80 micron. Reheating to just below reflux temperature (< 77 0C) and cooling at a rate of 1 °C/min yielded crystals having an average particle size of about 50 to 60 micron. In both instances, crystallization started at about 60 0C.
Reheating to reflux temperature (78 0C) and rapid cooling yielded crystals having an average particle size of about 20 to 30 micron.
The crystals were then filtered off, washed with ethanol parenteral grade (1 L/kg) and dried in vacuo at 50 0C in Tyvek bags so as to prevent dust formation.
HPLC analyses showed that the amount of the compound (I) was 99.4 % or more while the amount of (II-a) was 0.07 % or lower and compounds (II-b) and (III) were not detectable in any of the samples.
8 Batches were run, yielding product with a particle size distribution measured by laser diffraction as shown in Table 1.
Table 1
Figure imgf000014_0001
Example 2 : Scale up and equipment set upin Hastelloy C22 mini plant vessels of 30L, 60L and 160L.
A reactor was charged with 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piρeridinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]- pyrimidin-4-one palmitate ester and ethanol parenteral grade (8 L/kg) and heated to reflux temperature (78 - 79 0C) while stirring. The product dissolved at about 70 0C.
The reaction mixture is then cooled to room temperature whereupon the product crystallized. The thus obtained suspension was reheated again. The solution was cooled using differing cooling gradients (in consecutive experiments, the mixture was reheated and cooled again; after each cooling gradient, a sample was taken and isolated using a filter. The particle characteristics were determined.
HP LC analyses showed that the amount of (II-a) was 0.1 % or lower, and compounds (II-b) and (III) were not detectable in any of the samples.
Different batches were run, yielding product with a particle size distribution measured by laser diffraction as shown in Tables 2 to 4.
Table 2 : 30L scale experiments
Figure imgf000015_0001
Table 3 : 6OL scale experiments
Figure imgf000016_0001
Table 4 : 16OL scale experiments
Figure imgf000016_0002
Example 3 : Crystallization in stainless steel reactor of 50L All equipment was sterilized using dry heat sterilization.
A stainless steel reactor was charged with 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]- pyrimidin-4-one palmitate ester and ethanol parenteral grade (8 L/kg) and heated to reflux temperature (78 - 79 0C) while stirring. The product dissolved at about 70 0C. The solution was filtered at 76 0C over a sterile 0.22 μm filter into a sterile crystallization reactor. The sterile filter was then washed with heated ethanol (1 L/kg).
The filtrate was reheated to reflux and then cooled to room temperature whereupon the product crystallized. The thus obtained suspension was reheated again. The solution was cooled using differing cooling gradients (in consecutive experiments, the mixture was reheated and cooled again; after each cooling gradient, a sample was taken and isolated using a filter. The crystals were dried in vacuo at 50 0C in Tyvek bags so as to prevent dust formation and the particle characteristics were determined.
Different batches were run, yielding product with a particle size distribution measured by laser diffraction as shown in Table 5.
Table 5
Figure imgf000017_0001
Example 4 : Preparation of finished form.
Composition
Table 6
Figure imgf000018_0001
Equipment stainless steel (SS) containers
Grinding media (Zirconium beads) + stainless steel (SS) grinding chamber
- 0.2 μm filters
- 40 μm filter Filling unit Autoclave Dry heat oven
Manufacturing
Zirconium beads wear cleaned and rinsed using water for injections and then depyrogenised by dry heat (120 min at 26O0C). Water for injections was transferred into a SS container. Polysorbate 20 was added and dissolved by mixing. The solution was sterilized by filtration through a sterile 0.2 μm filter into a sterilized SS container. Paliperidone palmitate ester (sterile grade) as prepared in the previous examples was dispersed into the solution and mixed until homogeneous. The suspension was milled aseptically in the grinding chamber using Zirconium beads as grinding media until the required particle size was reached. The suspension was filtered aseptically through a 40 μm filter into a sterilized SS container
Water for injections was transferred into a SS container, citric acid monohydrate parenteral, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium hydroxide all use, polyethylene glycol 4000 were added and mixed until dissolved. This solution was sterilized by filtration through a sterile 0.2 μm filter and transferred aseptically into the suspension. The final suspension was mixed until homogeneous. The suspension was filled aseptically into sterile syringes. The target dose volume was between 0.25 ml and 1.50 ml depending on the dose needed.
Table 7
Figure imgf000019_0001
Sterilization
All aseptic manipulations and sterilization processes were carried out according to FDA and European regulatory guidelines.
Apparatus
Sterilization was done by steam sterilization (Fo > 15) of following equipment :
- SS containers
- Zirconium beads + grinding chamber
- 0.2 μm filters - 40 μm filter
- filling pump
Immediate container
- 1 ml long transparent plastic (COC) syringe with luer lock. - rubber tip cap, FM257/2 dark grey
- rubber plunger stopper, 1 ml long, 4023/50, Flurotec B2-40
- 2.25ml transparent plastic (COC) syringe with luer lock. - rubber tip cap, FM257/2 dark grey
- rubber plunger stopper, 1-3 ml, 4023/50, Flurotec B2-40
The empty syringes with pre-assembled tip-caps were sterilized by gamma-irradiation (dose > 25 kGy). The rubber plunger stoppers were sterilized by means of steam sterilization (F0 > 15).

Claims

Claims
1. A process for preparing aseptic crystalline 3-[2-[4-(6-fluoro-l ,2-benzisoxazol- 3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido- [l,2-a]pyrimidin-4-one palmitate ester of formula (I)
Figure imgf000021_0001
substantially free of 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)-l -piperidinyljethyl]- 6,7,8!9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one (II-a), 3-
[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7-dihydro-2-methyl- 4H-pyrido[l,2-a]pyrimidin-4-one (II-b), and 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3- yl)- 1 -piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-9-pentadecyl-4H-pyrido[ 1 ,2- a]pyrimidin-4-one (III), having an average particle size ranging from 20 to 150 μm, preferably from 20 to 80 μm, comprising the steps of a) heating 3-[2-[4-(6-fluoro- 1, 2-benzisoxazol-3-yl)-l -piperidinyl] ethyl] - 6,7,8,9-tetrahydro-9-hydroxy-2 -methyl -4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) and ethanol parenteral grade to 72 0C to 78 0C; b) filtering the solution over a sterile 0.22 μm filter into a sterile crystallization reactor; c) allowing 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)-l -piperidinyl]ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester to crystallize while cooling; and either d) filtering off the thus obtained crystals; or e) reheating the thus obtained suspension again to 72 0C to 78 0C; f) allowing 3-[2-[4-(6-fluoro- 1 ,2-benzisoxazol-3-yl)- 1 -piperidinyl] ethyl] - 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester to crystallize while cooling; and g) filtering off the crystals.
2. The process according to claim 1 comprising the steps a), b), c), e), f) and g).
3. The process according to claim 1 or 2 wherein the reheating in step e) is to reflux temperature.
4. The process according to claim 3 wherein the cooling in step f) is conducted as rapidly as possible.
5. The process according to claim 1 or 2 wherein the reheating step e) is conducted at < 77 0C.
6. The process according to claim 1 comprising the steps a), b), c) and d).
7. The process according to claim 1 comprising the farther steps of h) suspending the crystals obtained in steps d) or g) in a sterilized solution of water comprising a surfactant, a suspending agent and a buffer; i) grinding the suspension of step h) in the presence of a grinding medium to particles having a specific surface area > 4 m2/g; j) sieving the suspension of step i) to remove the grinding medium; k) diluting and mixing the solution of step j) with a sterilized solution of water optionally comprising a suspending agent, a buffer and an antioxidant; and 1) filling the sieved suspension into a sterile container.
8. Aseptic crystalline 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]- ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) substantially free of 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)- 1 -piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[ 1 ,2- a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)-l - piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one (II-b), and 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)-l -piperidinyl]ethyl]-6,7,8,9- tetrahydro-2-methyl-9-pentadecyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one (III), and having an average particle size ranging from 20 to 150 μm,
9. Aseptic crystalline 3-[2-[4-(6-fluoro- 1 ,2-benzisoxazol-3-yl)-l -piperidinyl]- ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one palmitate ester (I) containing less than 0.5 % of 3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl- 4H-pyrido[ 1 ,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3- yl)-l-piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one (II-b), and less than 0.01 % of 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-9-pentadecyl-4H-pyrido-
[l,2-a]pyrimidin-4-one (III), and having an average particle size ranging from 20 to 150 μm.
10. Aseptic crystalline 3-[2-[4-(6-fiuoro-l,2-benzisoxazol-3-yl)-l-ρiperidinyl]- ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one palmitate ester (I) substantially free of 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)- l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido- [l,2-a]pyrimidin-4-one (II-a), 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l- piperidinyl]ethyl]-6,7-dihydro-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one (II-b), and 3-[2-[4-(6-fluoro-l ,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9- tetrahydro-2-methyl-9-pentadecyl-4H-pyrido[ 1 ,2-a]pyrimidin-4-one (III), and having a specific surface area > 4 m /g.
PCT/EP2006/061694 2005-04-25 2006-04-20 Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester Ceased WO2006114384A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2006800138227A CN101163702B (en) 2005-04-25 2006-04-20 Preparation of sterile 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9- Tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one palmitate method
JP2008508198A JP5249748B2 (en) 2005-04-25 2006-04-20 Sterile 3- [2- [4- (6-Fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl] ethyl] -6,7,8,9-tetrahydro-9-hydroxy-2- Preparation of methyl-4H-pyrido [1,2-a] pyrimidin-4-onepalmitate
EP06754754A EP1879890A1 (en) 2005-04-25 2006-04-20 Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US11/912,452 US20080214808A1 (en) 2005-04-25 2006-04-20 Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
HK08108269.9A HK1117521B (en) 2005-04-25 2006-04-20 Process for preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one palmitate ester

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05103343.9 2005-04-25
EP05103343 2005-04-25
EP05103391.8 2005-04-26
EP05103391 2005-04-26

Publications (1)

Publication Number Publication Date
WO2006114384A1 true WO2006114384A1 (en) 2006-11-02

Family

ID=36847642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/061694 Ceased WO2006114384A1 (en) 2005-04-25 2006-04-20 Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester

Country Status (5)

Country Link
US (1) US20080214808A1 (en)
EP (1) EP1879890A1 (en)
JP (1) JP5249748B2 (en)
CN (1) CN101163702B (en)
WO (1) WO2006114384A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026621A1 (en) * 2007-08-29 2009-03-05 Alphapharm Pty Ltd Pharmaceutical compound & composition
WO2008021342A3 (en) * 2006-08-14 2009-04-09 Teva Pharma Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
WO2009070306A1 (en) * 2007-11-27 2009-06-04 Teva Pharmaceutical Industries Ltd. Processes for preparing crystal forms of 9-hydroxy-risperidone (paliperidone)
WO2009089076A3 (en) * 2008-01-10 2009-12-03 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
WO2011042450A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
WO2011053829A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutical Nv Dosing regimen associated with long-acting injectable paliperidone esters
US9320707B2 (en) 1997-11-17 2016-04-26 Janssen Pharmaceutica, N.V. Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
WO2016116831A1 (en) * 2015-01-19 2016-07-28 Aurobindo Pharma Limited Process for the preparation of paliperidone palmitate
US9439906B2 (en) 2007-12-19 2016-09-13 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
WO2016164218A1 (en) 2015-04-07 2016-10-13 Janssen Pharmaceuticals, Inc. Dosing regimen for missed doses for long-acting injectable paliperidone esters
US20210145836A1 (en) * 2012-05-09 2021-05-20 Icrom Spa Production of sterile active pharmaceutical ingredients
US11304951B1 (en) 2020-11-30 2022-04-19 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US11324751B1 (en) 2020-11-30 2022-05-10 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
WO2022111860A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
EP4137136A1 (en) 2021-08-20 2023-02-22 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080171876A1 (en) * 2007-05-10 2008-07-17 Santiago Ini Pure paliperidone and processes for preparing thereof
EP2547206B1 (en) 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
TWI577377B (en) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 Pharmaceutical composition
WO2012164582A1 (en) 2011-05-31 2012-12-06 Ramamohan Rao Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
JP6374387B2 (en) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． Antibody to risperidone hapten and use thereof
TR201816416T4 (en) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Antibodies to risperidone and their use.
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
TR201809424T4 (en) * 2012-08-21 2018-07-23 Janssen Pharmaceutica Nv Risperidone and paliperidone haptens.
WO2016157061A1 (en) 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
WO2016199170A2 (en) * 2015-06-10 2016-12-15 Cipla Limited Paliperidone palmitate particles and compositions thereof
JP6851318B2 (en) * 2015-11-26 2021-03-31 持田製薬株式会社 Pyrazole derivative crystals
CN108431040B (en) 2015-12-17 2022-07-26 詹森药业有限公司 Antibodies to risperidone and uses thereof
CN113024546B (en) * 2019-12-25 2022-06-10 江苏晶立信医药科技有限公司 Preparation method of small-particle-size paliperidone palmitate
CN111533737A (en) * 2020-05-22 2020-08-14 烟台大学 4-Flupaliperidone palmitate and its preparation method and application
CN116925071A (en) * 2023-06-14 2023-10-24 丽珠医药集团股份有限公司 Preparation method of paliperidone palmitate photodegradation impurity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025354A2 (en) * 1997-11-17 1999-05-27 Janssen Pharmaceutica N.V. Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025354A2 (en) * 1997-11-17 1999-05-27 Janssen Pharmaceutica N.V. Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1879890A1 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320707B2 (en) 1997-11-17 2016-04-26 Janssen Pharmaceutica, N.V. Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
WO2008021342A3 (en) * 2006-08-14 2009-04-09 Teva Pharma Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
WO2009026621A1 (en) * 2007-08-29 2009-03-05 Alphapharm Pty Ltd Pharmaceutical compound & composition
WO2009070306A1 (en) * 2007-11-27 2009-06-04 Teva Pharmaceutical Industries Ltd. Processes for preparing crystal forms of 9-hydroxy-risperidone (paliperidone)
EP2234617B1 (en) 2007-12-19 2021-03-31 Janssen Pharmaceutica NV Dosing regimen associated with long acting injectable paliperidone esters
EP3909585A1 (en) 2007-12-19 2021-11-17 Janssen Pharmaceutica NV Dosing regimen associated with long acting injectable paliperidone esters
US9439906B2 (en) 2007-12-19 2016-09-13 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
WO2009089076A3 (en) * 2008-01-10 2009-12-03 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
WO2011042450A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
WO2011053829A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutical Nv Dosing regimen associated with long-acting injectable paliperidone esters
US20210145836A1 (en) * 2012-05-09 2021-05-20 Icrom Spa Production of sterile active pharmaceutical ingredients
WO2016116831A1 (en) * 2015-01-19 2016-07-28 Aurobindo Pharma Limited Process for the preparation of paliperidone palmitate
EP4349323A2 (en) 2015-04-07 2024-04-10 JANSSEN Pharmaceutica NV Dosing regimen for missed doses for long-acting injectable paliperidone esters
US10143693B2 (en) 2015-04-07 2018-12-04 Janssen Pharmaceuticals, Inc. Dosing regimen for missed doses for long-acting injectable paliperidone esters
WO2016164218A1 (en) 2015-04-07 2016-10-13 Janssen Pharmaceuticals, Inc. Dosing regimen for missed doses for long-acting injectable paliperidone esters
EP3744326A1 (en) 2015-04-07 2020-12-02 Janssen Pharmaceuticals, Inc. Dosing regimen for missed doses for long-acting injectable paliperidone esters
US11304951B1 (en) 2020-11-30 2022-04-19 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
WO2022111859A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
WO2022111860A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
WO2022111858A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US11439647B2 (en) 2020-11-30 2022-09-13 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US11324751B1 (en) 2020-11-30 2022-05-10 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
EP4356966A2 (en) 2020-11-30 2024-04-24 JANSSEN Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
EP4385564A2 (en) 2020-11-30 2024-06-19 JANSSEN Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
US12053474B2 (en) 2020-11-30 2024-08-06 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US12208100B2 (en) 2020-11-30 2025-01-28 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
EP4137136A1 (en) 2021-08-20 2023-02-22 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US12472184B2 (en) 2021-08-20 2025-11-18 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Also Published As

Publication number Publication date
JP2008538780A (en) 2008-11-06
US20080214808A1 (en) 2008-09-04
CN101163702A (en) 2008-04-16
CN101163702B (en) 2011-09-07
JP5249748B2 (en) 2013-07-31
HK1117521A1 (en) 2009-01-16
EP1879890A1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
EP1879890A1 (en) Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
CA2695178C (en) Methods for producing aripiprazole suspension and freeze-dried formulation
CZ253893A3 (en) Agent containing nano-particles and process for preparing nano-particles
JP4211965B2 (en) Aqueous suspension of submicron 9-hydroxyrisperidone fatty acid ester
EP0605024A2 (en) Use of purified surface modifiers to prevent particle aggregation during sterilization
JP5160702B2 (en) Preparation of phospholipid suspensions containing lipid blends
CZ263393A3 (en) The use of ionic modifiers of cloud point for eliminating aggregation of particles during sterilization
CN1870979A (en) Process for producing substantially solvent-free small particles
EP1762249A2 (en) Freeze-dried pantoprazole preparation and pantoprazole injection
EP3723760B1 (en) One step milling process for preparing micronized paliperidone esters
AU2010201801A1 (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CN108379231A (en) The lyophilized preparation of Aripiprazole
HK1117521B (en) Process for preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one palmitate ester
JP2008094722A (en) Method for producing immunoglobulin preparation
WO2023203255A1 (en) Freeze dried compositions
HK1141727A (en) Methods for producing aripiprazole suspension and freeze-dried formulation
HU231003B1 (en) Process for the preparation of lyophilized,nanoscale protein suspension suitable for the examination of lymphatic circulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006754754

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11912452

Country of ref document: US

Ref document number: 200680013822.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008508198

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 8487/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006754754

Country of ref document: EP